Dexcom's Stelo Expands CGMs to Non-Insulin Type 2

episode

Vanguards of Healthcare by Bloomberg Intelligence not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Vanguards of Healthcare by Bloomberg Intelligence

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care 53 min · 02 Apr 2026

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough 1h 2m · 31 Mar 2026

Abridge Moving AI From Scribing to Clinical Workflows 54 min · 26 Mar 2026

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 44 min · 19 Mar 2026

Xaira’s War on Trial-and-Error Drug Development 56 min · 12 Mar 2026

AVS’ Toland on Next Lithotripsy Launch 43 min · 05 Mar 2026

All episodes from Vanguards of Healthcare by Bloomberg Intelligence →

Report any issue

Source

Recorded04 Apr 2024

Publisheromnycontent.com ↗

Handlerec:13806600

Show notes

Dexcom is expanding its portfolio of continuous glucose monitors (CGMs) with the launch of Stelo, balancing the needs of patients and payors to maximize the use of the technology, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down with BI analyst Matt Henriksson for an in-depth interview about how G7, Dexcom’s flagship CGM, is capturing share in every market it’s in, how the launch of Stelo opens up CGM access to nearly 25 million Type 2 diabetes patients in the US and how any patient can order the new CGM without a prescription.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in